Molecular Partners AG (MOLN)
NASDAQ: MOLN · Real-Time Price · USD
3.895
-0.015 (-0.38%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Molecular Partners AG Revenue
In the year 2024, Molecular Partners AG had annual revenue of 4.97M CHF, down -29.38%.
Revenue (ttm)
4.97M CHF
Revenue Growth
-29.38%
P/S Ratio
25.93
Revenue / Employee
31,356 CHF
Employees
159
Market Cap
142.24M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
MOLN News
- 2 days ago - Molecular Partners Announces all Board Proposals Approved at Annual General Meeting - GlobeNewsWire
- 24 days ago - Molecular Partners to hold three poster presentations at AACR 2025 - GlobeNewsWire
- 24 days ago - Molecular Partners Publishes Invitation to Annual General Meeting 2025 - GlobeNewsWire
- 6 weeks ago - Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 - GlobeNewsWire
- 7 weeks ago - Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call - GlobeNewsWire
- 3 months ago - Molecular Partners: Leveraging Its Biologics Platform Into Early Clinical Programs - Seeking Alpha
- 3 months ago - Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire